Clinical Need

Obesity and diabetes are debilitating conditions affecting more than 1 billion patients worldwide; they are the most costly chronic conditions to healthcare systems surpassing cardiovascular diseases and cancer and their prevalence is increasing and impacting every corner of the globe.

Metabolic surgery remains the only sustainable solution to treat obesity and the resulting diabetes, but surgery is invasive, is associated with complexity, complications, and high costs. The new GLP-1 receptor agonists drugs can be effective but very costly, need to be taken long-term, leading to high burden on payors and patient non-compliance. As for the commercially available minimally invasive endoscopic solutions, although safe, are not effective.